Free Trial

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

$40.46
-0.29 (-0.71%)
(As of 07/12/2024 ET)

Bristol-Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$59.07
45.99% Upside
High Forecast$85.00
Average Forecast$59.07
Low Forecast$41.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
7 Buy rating(s)
Hold
13 Hold rating(s)
15 Hold rating(s)
15 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$59.07$60.00$61.12$75.44
Forecasted Upside45.99% Upside12.81% Upside12.72% Upside8.38% Upside
Get Bristol-Myers Squibb Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bristol-Myers Squibb Stock vs. The Competition

TypeBristol-Myers SquibbMedical CompaniesS&P 500
Consensus Rating Score
2.12
2.71
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside45.99% Upside994.16% Upside9.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$43.00 ➝ $41.00-0.28%
4/26/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00+6.29%
4/18/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00+8.11%
4/1/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/11/2024Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/6/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$77.00 ➝ $54.00+12.50%
1/3/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$68.00 ➝ $60.00+13.67%
11/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Brayer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$68.00 ➝ $55.00+8.86%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$55.00+4.92%
11/2/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$68.00 ➝ $54.00+5.30%
10/30/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$81.00 ➝ $69.00+35.48%
10/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$56.00 ➝ $50.00-5.63%
10/27/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold$55.00 ➝ $53.00+0.03%
10/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$70.00 ➝ $60.00+6.29%
10/6/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$84.00+47.91%
9/15/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$80.00 ➝ $66.00+11.47%
7/28/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$90.00 ➝ $85.00+39.89%
7/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$72.00 ➝ $66.00+5.13%
7/10/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
7/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$66.00+5.35%
4/28/202351job
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
3/6/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$62.00-10.53%
10/10/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
9/14/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$82.00 ➝ $76.00+6.98%
7/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$80.00 ➝ $85.00+13.62%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:47 AM ET.

BMY Forecast - Frequently Asked Questions

What is Bristol-Myers Squibb's forecast for 2024?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol-Myers Squibb is $59.07, with a high forecast of $85.00 and a low forecast of $41.00.

Should I buy or sell Bristol-Myers Squibb stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There is currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.

Does Bristol-Myers Squibb's stock price have much upside?

According to analysts, Bristol-Myers Squibb's stock has a predicted upside of 13.66% based on their 12-month stock forecasts.

What analysts cover Bristol-Myers Squibb?

Bristol-Myers Squibb has been rated by research analysts at Barclays, BMO Capital Markets, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Bristol-Myers Squibb more than its competitors?

Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.


This page (NYSE:BMY) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners